title: Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population.
abstract: BACKGROUND
  Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours.
  
  
  OBJECTIVE
  Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population.
  
  
  METHODS
  Twenty-four French university departments of urology participated in this retrospective study.
  
  
  METHODS
  All patients were treated according to current European Association of Urology guidelines.
  
  
  METHODS
  Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods.
  
  
  CONCLUSIONS
  The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥ 3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design.
  
  
  CONCLUSIONS
  RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
authors.affiliation: Department of Urology, Foch Hospital, Suresnes, France. y.neuzillet@hopital-foch.org
authors.forename: Yann
authors.initials: Y
authors.lastname: Neuzillet
authors.forename: Xavier
authors.initials: X
authors.lastname: Tillou
authors.forename: Romain
authors.initials: R
authors.lastname: Mathieu
authors.forename: Jean-Alexandre
authors.initials: JA
authors.lastname: Long
authors.forename: Marc
authors.initials: M
authors.lastname: Gigante
authors.forename: Philippe
authors.initials: P
authors.lastname: Paparel
authors.forename: Laura
authors.initials: L
authors.lastname: Poissonnier
authors.forename: Hervé
authors.initials: H
authors.lastname: Baumert
authors.forename: Bernard
authors.initials: B
authors.lastname: Escudier
authors.forename: Hervé
authors.initials: H
authors.lastname: Lang
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rioux-Leclercq
authors.forename: Pierre
authors.initials: P
authors.lastname: Bigot
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Bernhard
authors.forename: Laurence
authors.initials: L
authors.lastname: Albiges
authors.forename: Laurence
authors.initials: L
authors.lastname: Bastien
authors.forename: Jacques
authors.initials: J
authors.lastname: Petit
authors.forename: Fabien
authors.initials: F
authors.lastname: Saint
authors.forename: Franck
authors.initials: F
authors.lastname: Bruyere
authors.forename: Jean-Michel
authors.initials: JM
authors.lastname: Boutin
authors.forename: Nicolas
authors.initials: N
authors.lastname: Brichart
authors.forename: Georges
authors.initials: G
authors.lastname: Karam
authors.forename: Julien
authors.initials: J
authors.lastname: Branchereau
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Ferriere
authors.forename: Hervé
authors.initials: H
authors.lastname: Wallerand
authors.forename: Sébastien
authors.initials: S
authors.lastname: Barbet
authors.forename: Hicham
authors.initials: H
authors.lastname: Elkentaoui
authors.forename: Jacques
authors.initials: J
authors.lastname: Hubert
authors.forename: Benoit
authors.initials: B
authors.lastname: Feuillu
authors.forename: Pierre-Etienne
authors.initials: PE
authors.lastname: Theveniaud
authors.forename: Arnauld
authors.initials: A
authors.lastname: Villers
authors.forename: Laurent
authors.initials: L
authors.lastname: Zini
authors.forename: Aurélien
authors.initials: A
authors.lastname: Descazeaux
authors.forename: Morgan
authors.initials: M
authors.lastname: Roupret
authors.forename: Benoit
authors.initials: B
authors.lastname: Barrou
authors.forename: Karim
authors.initials: K
authors.lastname: Fehri
authors.forename: Thierry
authors.initials: T
authors.lastname: Lebret
authors.forename: Jacques
authors.initials: J
authors.lastname: Tostain
authors.forename: Jean-Etienne
authors.initials: JE
authors.lastname: Terrier
authors.forename: Nicolas
authors.initials: N
authors.lastname: Terrier
authors.forename: Lucille
authors.initials: L
authors.lastname: Martin
authors.forename: Fabrice
authors.initials: F
authors.lastname: Dugardin
authors.forename: Ismaël
authors.initials: I
authors.lastname: Galliot
authors.forename: Frédéric
authors.initials: F
authors.lastname: Staerman
authors.forename: Marie-Dominique
authors.initials: MD
authors.lastname: Azemar
authors.forename: Jacques
authors.initials: J
authors.lastname: Irani
authors.forename: Baptiste
authors.initials: B
authors.lastname: Tisserand
authors.forename: Marc-Olivier
authors.initials: MO
authors.lastname: Timsit
authors.forename: Federico
authors.initials: F
authors.lastname: Sallusto
authors.forename: Pascal
authors.initials: P
authors.lastname: Rischmann
authors.forename: Laurent
authors.initials: L
authors.lastname: Guy
authors.forename: Antoine
authors.initials: A
authors.lastname: Valeri
authors.forename: Charles
authors.initials: C
authors.lastname: Deruelle
authors.forename: Abdel-Rahmène
authors.initials: AR
authors.lastname: Azzouzi
authors.forename: Denis
authors.initials: D
authors.lastname: Chautard
authors.forename: Arnaud
authors.initials: A
authors.lastname: Mejean
authors.forename: Laurent
authors.initials: L
authors.lastname: Salomon
authors.forename: Jérôme
authors.initials: J
authors.lastname: Rigaud
authors.forename: Christian
authors.initials: C
authors.lastname: Pfister
authors.forename: Michel
authors.initials: M
authors.lastname: Soulié
authors.forename: François
authors.initials: F
authors.lastname: Kleinclauss
authors.forename: Lionel
authors.initials: L
authors.lastname: Badet
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Patard
mesh_terms: D000328:Adult; D000368:Aged; D002292:Carcinoma, Renal Cell / Q000209:etiology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D016009:Chi-Square Distribution; D005260:Female; D005602:France; D006801:Humans; D053208:Kaplan-Meier Estimate; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000401:mortality / Q000628:therapy; D007680:Kidney Neoplasms / Q000209:etiology* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D018570:Risk Assessment; D012307:Risk Factors; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome